ENDPOINTS

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant announced a deal on Monday to license a Phase 1 ...

Feb 10, 2025 - 21:16
 0
Eli Lilly inks $630M deal for Phase 1 MASH candidate
Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant announced a deal on Monday to license a Phase 1 ...
Read More

Tags:

Previous Article

Scientists grew human-like teeth in pigs. Could it lead to living tooth replacem...

Next Article

In emergency decision, James Webb telescope will study 'city-killer' asteroid 20...

Related Posts

Acelyrin and Alumis to merge in deal combining cash, assets

Acelyrin and Alumis to merge in deal combining cash, as...

Feb 9, 2025  0

Longtime Sandoz exec announces retirement; Lilly appoints head of India

Longtime Sandoz exec announces retirement; Lilly appoin...

Feb 9, 2025  0

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

J&J, Intra-Cellular quickly sealed $14B deal as three o...

Feb 9, 2025  0